key: cord-0835827-zd9257zi
authors: Goncharov, N. V.; Vasilyev, K. A.; Kudryavtsev, I. V.; Avdonin, P. P.; Belinskaia, D. A.; Stukova, M. A.; Shamova, O. V.; Avdonin, P. V.
title: Experimental Search for New Means of Pathogenetic Therapy COVID-19: Inhibitor of H2-Receptors Famotidine Increases the Effect of Oseltamivir on Survival and Immune Status of Mice Infected by A/PR/8/34 (H1N1)
date: 2022-03-05
journal: J Evol Biochem Physiol
DOI: 10.1134/s0022093022010203
sha: 4b3778e50995408a0d623247244ea2f9dece53d0
doc_id: 835827
cord_uid: zd9257zi

The development of drugs for the therapy of COVID-19 is one of the main problems of modern physiology, biochemistry and pharmacology. Taking into account the available information on the participation of mast cells and the role of histamine in the pathogenesis of COVID-19, as well as information on the positive role of famotidine in the prevention and treatment of coronavirus infection, an experiment was carried out using famotidine in a mouse model. We used a type A/PR/8/34 (H1N1) virus adapted to mice. The antiviral drug oseltamivir (Tamiflu), which belongs to the group of neuraminidase inhibitors, was used as a reference drug. The use of famotidine in combination with oseltamivir can increase survival, improve the dynamics of animal weight, reduce the level of NKT cells and increase the level of naive T-helpers. Further studies of famotidine in vivo should be aimed at optimizing the regimen of drug use at a higher viral load, as well as with a longer use of famotidine.

Abbreviations: ACE2-angiotensin converting enzyme 2; APTT-activated partial thromboplastin time; ARDS-acute respiratory distress syndrome; AT1-angiotensin II receptor type 1; COVID 19coronavirus disease 2019; COX 2-cyclooxygenase 2; CRP-C reactive protein; CT-computed tomography; DIC-disseminated intravascular coagulation; EC-endothelial cells; DCE-developing chicken embryos; ELA-endogenous lipid autacoids; FS-forward scattering; GM CSF-granu locyte macrophage colony stimulating factor; GPCR-G protein coupled receptors; IL 1/6/8interleukin 1/6/8; MAS-G protein coupled receptor that binds angiotensin (1 7), a metabolite of angiotensin II; MCAS-mast cell activation syndrome; MCP 1-monocyte chemoattractant pro tein 1; NET-neutrophil extracellular traps; NK-natural killers; NKT cells-Natural killer T cell; NRP-neuropilin; NSAID-non steroidal anti inflammatory drugs; PAF-platelet activating factor; PEEP-positive end expiratory pressure; PGE-prostaglandin E; ROS-reactive oxygen species; SARS CoV 2-severe acute respiratory syndrome coronavirus 2; SS-side scattering; TMPRSS2type II transmembrane bound serine protease; TNF α-tumor necrosis factor alpha; vWF-von Willebrand factor

The coronavirus pandemic has spurred research of the role of endothelial cells (EC) in the patho genesis of COVID 19. EC damage caused by SARS CoV 2 exacerbates endothelial dysfunction that commonly occurs with aging, hypertension, and obesity. A sharp increase in endothelial dys function as a result of damage by SARS CoV 2 causes the development of acute respiratory dis tress syndrome (ARDS). One of the main prob lems in studying the pathogenetic mechanisms of the development of COVID 19 is the molecular biological characteristics of EC in different organs and within one organ (primarily in the lungs, but also in the kidneys, heart and brain), since the virus penetrates into different cells with varying degrees of probability and causes consequences of different nature and intensity of manifestation [1] . In this case, the main pathogenetic consequence, which largely determines the outcome of the dis ease, is hypercoagulation of blood as a result of massive release of von Willebrand factor (vWF) by EC [2, 3] . Angiotensin converting enzyme 2 (ACE2) is the main glycoprotein used by SARS CoV 2 to enter cells. The penetration of the virus into cells is associated with a decrease in the num ber of expressed ACE2 molecules, with subse quent disruption of the functional balance of the functional axes ACE/AngII/AТ1 and ACE2/ Ang(1 7)/Mas [4] . Other coronavirus "receptors" on EC have also been determined, such as CD209L (L SIGN), CD209 (DC SIGN) [5] , neuropilin receptors (NRP) [6] and CD147/basi gin [7] . CD209L is especially strongly expressed in epithelial and endothelial cells of the lungs and kidneys, mediating the entry of SARS CoV 2 into cells [5] . It is also well known that penetration of SARS CoV 2 into cells requires proteolytic acti vation of the spike protein, which involves TMPRSS2 peptidases, furin, and cathepsins [1] .

According to some scientists, there are two main pathogenetic factors that cause alveolar edema in COVID 19: infection of cells with virus SARS CoV 2 and degranulation of mast cells with the release of many compounds that can affect the function of cell and basement mem branes, glycocalyx and the integrity of tight junc tions [8] . Among these compounds, histamine, bradykinin, heparin, tryptase, and cytokines are of the greatest interest from the point of view of the pathogenesis of COVID 19. In the outpatient setting, early COVID 19 is usually indistinguish able from other "flu like" illnesses with symp toms ranging from sore throat, headache and diarrhea to fever, cough and myalgia. However, in these first few days, COVID 19 can be associated with anosmia [9] . Severe forms of COVID 19 are characterized not only by pneumonia and ARDS, but also by the development of systemic multiple organ failure, as a result of an uncontrolled "cyto kine storm", including the release of pro inflam matory cytokines (such as TNF α, IL 6, IL 1, IL 8 and MCP 1) [10] . However, this storm is not the only, predetermined and irreversible event. First, SARS CoV 2 causes massive cell death with the formation of cellular debris, which activates inflammasomes not only in innate immune cells, but also in EC, triggering the so called "eicosanoid storm". Eicosanoid storm is a surge in the proinflammatory bioactive lipid mediators (such as prostaglandins and leukot rienes) that fuel local inflammation [11, 12] . Sec ondly, there has been a recent paradigm shift in the concept of inflammation, which consists in the fact that in the process of inflammation itself there is a mechanism for its cessation thanks to specialized endogenous lipid autacoids (ELA)resolvins, lipoxins and protectins, which perform not so much anti inflammatory but restrictive functions. ELA promote removal of cellular debris by macrophages and counteracts excessive release of proinflammatory cytokines/chemok ines [13] . It is believed that the disorder in the mechanism of limiting and stopping inflamma tion plays a decisive role in maintaining patholog ical inflammation in COVID 19 and other viral infections [14] . The disorder can be caused by common anti inflammatory agents such as non steroidal anti inflammatory drugs (NSAID) and cyclooxygenase 2 inhibitors (COX 2, COX 2), as they indiscriminately inhibit the eicosanoid path ways that produce these "control mediators" and thereby impede the process of active limitation of inflammation [13, 14] .

The role of EC and reactive oxygen species (ROS) in the generation of these lipid autacoids has not been studied.

The action of histamine is mediated by four types of receptors-H1, H2, H3 and H4. The most well known functions of H1 receptors are the regulation of vasodilatation and bronchocon striction, since the receptors of this type are local ized mainly on endothelial and smooth muscle cells of blood vessels. H2 receptors are mainly involved in modulating gastric secretion of pari etal cells [15] . In sepsis, histamine, through the activation of H1 and H2 receptors, contributes to the development of target organ failure. The use of H1 and H2 receptor antagonists has shown that H1 and H2 receptors are involved in septic dam age to the lungs and liver, but only H2 receptors contribute to septic kidney damage [16] .

Most of the current reviews explain the clinical and pathogenetic knowledge of COVID 19 based on standard models of antiviral innate and adap tive immune response that do not consider the role of histamine and mast cells as its primary source. The existing schemes describe the cellular response associated with inflammation and the participation of monocytes, macrophages, adap tive T and B cells [17, 18] . This type of immune response is also used to explain the pulmonary intravascular coagulopathy associated with COVID 19 [19] . We are supporters of an alterna tive paradigm, according to which the activation of mast cells caused by infection with SARS CoV 2, the release of histamine and pro inflam matory cytokines (mainly TNF α) from mast cells is the most important link in the pathological cascade and is responsible for most of the atypical symptoms associated with COVID 19 [8, 20, 21] . This model is consistent with histopathological data and is supported by clinical and pharmaco logical data suggesting potential benefits of hista mine H2 receptor blockade with famotidine. This model is also supported by a significant overlap between the clinical signs of the initial phase of COVID 19 and mast cell activation syndrome (MCAS) [22] [23] [24] , similarities with the clinical signs of Dengue hemorrhagic fever and shock syndrome (including T lymphocyte depletion) in the later stages of COVID 19 [25, 26] . In addi tion, the consequences of COVID 19 such as stroke and cardiovascular disease correspond to Kounis syndrome [27] , as evidenced by the data on an increased number of mast cells in the walls of the alveolar septa and lung parenchyma infected with SARS CoV 2 [28] .

The aim of this work is to theoretically substan tiate and experimentally verify the effectiveness of the H2 receptor inhibitor famotidine as a poten tial component of the complex for the pathoge netic therapy of COVID 19. In the experimental search for new means of pathogenetic therapy for coronavirus infection, it is important to under stand that mice are only carriers of coronavirus infection. However, this problem is solved by using other strains of influenza that cause a similar condition in mice, in particular the development of immune imbalance, cytokine storm and ARDS in the terminal stage of the disease, which is the direct cause of death. One of the viral strains caus ing this disease in mice is A/PR/8/34 (H1N1) [29] .

Experiments with animals were carried out in accordance with the European Convention for 20 mg of famotidine were diluted in 2 mL of a mixture of DMSO + propylene glycol, the stock solution of 10 mg/mL was stored in the refrigera tor. Working solutions for intragastric administra tion were prepared extempore: 100 μL of the stock solution was diluted in 2.4 mL of saline or osel tamivir solution, each mouse was injected through a tube with a volume of 100 μL per 10 g, which corresponds to a dose of famotidine 4 mg/kg. Drug administration was started on the day of infection (2 hours before) and continued for the next 4 days. The duration of the experiment was 14 days. A more detailed description of a similar model is given in [30] .

Blood sampling for analysis was carried out on the 4th day after infection. Blood was taken from the cheek using a scarifier, as described in [31] .

In brief, 50 μL of rat whole peripheral blood were stained on surface expression with the fol lowing specific fluorochrome conjugated mono clonal antibodies: anti rat CD44 FITC (cat. . After incubation at room temperature in the dark for 15 min, erythrocytes were lysed for 15 min with 0.25 mL of OptiLyse C Solution (Beckman Coulter, Inc., USA). Next, 0.25 mL of sterile PBS were added to each samples, after incubation at room temperature in the dark for 15 min lympho cyte cell suspensions were washed (7 min 330 g) twice with a buffer (sterile phosphate buffered saline (PBS) containing 2% of heat inactivated fetal bovine serum, Sigma Aldrich, USA) and were resuspended in 0.5 mL of the PBS contain ing 2% of neutral buffered formalin solution (Sigma Aldrich, USA). Sample acquisition was performed using a CytoFlex cytometer (Beckman Coulter, Inc., USA), equipped with 405, 488 and 638 nm lasers. At least 20000 lymphocytes were analyzed in each sample (doublets were excluded from the analysis using FS area versus FS weight dot plot). Obtained data were analyzed with Kaluza software (Beckman Coulter, Inc., USA). The data obtained were expressed as a percentage of the population of cells of interest. Figure 1 shows data on survival (left) and body weight dynamics (right) in mice infected with influenza A/PR/8/34 and treated with oseltami vir, famotidine, and their combination. Kaplan Meier curves represent the percentage of animals that survived at various time points after infection. The first death of animals was recorded on the 7th day after infection in the (+)control (2 out of 10 mice) and Famotidine (1 out of 10) groups. During 14 days of the experiment, 6 animals died in each of these two groups, which corresponds to a survival rate of 40%. After 9 days, death of one mouse from the oseltamivir group was registered, after which not a single death occurred in this group of animals, which corresponds to a survival rate of 90%. In the group of animals that received a mixture of famotidine and oseltamivir, no deaths were registered for 14 days, which corre sponds to 100% survival. Animals of this group showed the best dynamics of body weight (mini mal decrease) and outwardly looked better than animals of other experimental groups.

Multicolor flow cytometry was used to identify the main subpopulations of lymphocytes. T lym phocytes were isolated based on the presence of CD3 on the cell surface, after which the total pool of T cells was divided into T helpers with CD3+CD4+ phenotype, cytotoxic T lymphocytes with CD3+CD8+ phenotype, and NKT cells with CD3+CD49b+ phenotype. Additionally, popula tions of B lymphocytes (CD19+ cells) and natu ral killer cells (CD3 CD49b+) were isolated within the general pool of lymphocytes. The results of the analysis of the relative content of these types of lymphocytes are shown in Fig. 2 . Thus, there were differences in the content of NKT cells between the groups of intact animals and animals receiving both drugs (14.4 ± 4.6 ver sus 9.1 ± 3.0 at p = 0.012, respectively).

It is known that after activation, NKT cells are capable of producing large amounts of interferon gamma, IL 4 and granulocyte macrophage colony stimulating factor (GM CSF), as well as many other cytokines and chemokines (IL 2, IL 13, IL 17, IL 21 and TNF alpha). NKT cells pro vide support and assistance to B cells [32] . At the same time, there is eosinophil mediated inflam mation in the lungs of COVID 19 patients, as well as an increased NKT cell response associated with ARDS and pneumonia [33] .

In the course of further studies, T helpers and cytotoxic T lymphocytes were divided into four main subpopulations of cells: "naive" CD44 low to dim CD62L + cells, central memory (CM) cells with the CD44 hi CD62L + phenotype, effector memory (EM) cells CD44hiCD62Land differentiated effector cells CD44 low to dim CD62L -. The results are presented in Fig. 3 . It was shown that the combined use of oseltamivir and famoti dine is accompanied by an increase of "naive" T helper cells in the circulation, which are capable of recognizing a wide range of invading pathogens, relative to the values obtained for animals receiving only famotidine (72 ± 6.4 versus 61.4 ± 10 at p = 0.040, respectively). In addition, in animals treated with famotidine, the proportion of T helpers of central memory increased relative to control ani mals and animals from the oseltamivir + famoti dine group (15.3 ± 3.4 versus 10.8 ± 2.7 and 11.1 ± 1.8 at p = 0.004 and p = 0.012, respec tively). Moreover, when analyzing the subpopula tion composition of cytotoxic T lymphocytes, we also noted significant differences in the content of EM cells between the control group and the group of animals receiving famotidine (16.2 ± 2.6 versus 20.2 ± 6.4 at p = 0.004, respectively).

In severe cases of COVID 19, there is a decrease in lymphocyte count, but an increase in white blood cell count and neutrophil to lym phocyte ratio (NLR). In especially severe cases, an increased level of inflammatory cytokines is associated with a significant decrease in the num ber of T lymphocytes, especially T helpers [34] . Another study found that, in severe cases of COVID 19, the cellular response is characterized by lymphocytopenia with a low content of naive Fig. 3 : squares-intact animals (n = 5); triangles-animals of the control group (n = 10); inverted triangles-group of animals treated with oseltamivir (n = 10); diamonds-a group of animals that received famotidine (n = 10); circles-a group of animals treated with oseltamivir and famotidine (n = 10). Results are shown as median and interquartile range Med (Q25; Q75). Differences between groups were significant according to analysis of variance (ANOVA) and Tukey's test. * p < 0.05. T helper cells, along with CD8+ T cells and natu ral killer cells [35] . It is important to note that CD8+ and NK cells in surviving patients recov ered after 8-14 days, while naive Th cells did not recover.

The pathophysiological effect of SARS CoV 2 depends on a number of epigenetic factors (life style, diet, smoking, etc.) that affect the balance of the activity of the functional axes ACE/AngII/ AT1 (vasoconstriction, ROS generation, inflam mation) and ACE2/Ang(1 7)/Mas (vasodilation, antioxidant and anti inflammatory effects) [36] . SARS CoV 2, in comparison with SARS CoV, is more contagious, but less virulent [37] , which is associated with the different tropism of the viruses to different receptors, the spectrum and expres sion of the receptors in different organs and tis sues [5] . Activation of AT1 receptors by angiotensin II determines the generation of ROS in endothelial cells and vascular smooth muscle cells, as well as in the paraventricular nuclei of the hypothalamus [38] . The activity of ACE is associ ated not only with the formation of angiotensin II: a relationship has been found between the activity of this enzyme and the degree of mobili zation of innate cellular immunity during tumor growth and infection, as well as the degree of expression of the proteins of the main histocom patibility complex class I and II [39] .

The available scanty data on pathological changes in tissues in the early stages of COVID 19 support the assumptions about the combined effect of viral infection and the effects of hista mine in the lungs. Thus, two different disease pat terns are identified when examining lung tissue removed from a cancer patient at an early stage of COVID 19 [40] . In some lung tissue samples, there is a common mononuclear inflammatory pattern of interstitial pneumonitis with fibrinous exudate, which is caused by the viral infection. It should be noted that there are virtually no neutro phils or eosinophils in the inflammatory infiltrate. One of the explanations is that histamine activa tion of H2 receptors in neutrophils suppresses their effector functions, including generation of superoxide anion [41, 42] , PAF induced chemo taxis [43] , and biosynthesis of leukotrienes [44] .

The functional activity of eosinophils is also suppressed upon activation of H2 receptors: the binding of histamine suppresses degranulation, decreasing the release of eosinophil peroxidase [45] , and at higher concentrations inhibits the che motaxis of eosinophils [46] . In other samples of lung tissue from patients with COVID 19, intersti tial and alveolar edema occurs, while alveolar septa retain their normal architecture [47, 48] . This is an atypical picture observed with a viral infection, since there is no inflammation, and the fluid is a transudate. This is consistent with the concept of dysregulation of the fluid barrier due to the effect of histamine or other mast cell products on EC, peri cytes, or type II pneumocytes. It is assumed that increased endothelial permeability is due to the activation of the H1 receptor by histamine, although no one has investigated the degree of expression of other types of histamine receptors on EC, smooth muscle cells or other ones. The presence of H2 receptors on mast cells is import ant: an increase in the intracellular level of cAMP, for example, with the help of forskolin, is used to inhibit the release of histamine from basophils and human mast cells [49] . Histamine can act as an autocrine regulator of mast cells in PGE2 depen dent cytokine and TNF α release; this autocrine feedback is mediated by H2 and H3 receptors [50] . Pulmonary edema associated with mast cell degranulation may correlate with the early phase of the so called "quiet" or "happy" hypoxia [51] . In African green monkeys infected with SARS CoV 2, the number of mast cells in the lung parenchyma significantly increases, correlating with the severity of pneumonia [8] . These results are supported by autopsy data from a patient who died 5 days after the onset of symptoms of COVID 19: non inflammatory transudative edema is clearly visible on micrographs [52] . In both cases, non inflammatory pulmonary edema at an early stage of COVID 19 disease is accom panied by the release of histamine by mast cells [52] . Mast cell degranulation is correlated with the natural course of COVID 19, which goes through functionally and clinically different early and late phases. Most SARS CoV 2 infections follow the typical early phase of any lower respira tory tract virus, in which most patients are asymp tomatic or of minimal severity, and a minority develop ARDS at a later stage. Towards the end of the first week of symptom onset, COVID 19 patients develop shortness of breath. This occurs several days after cough and fever, which is not typical for other influenza viruses [53] . When examining patients with COVID 19 who have shortness of breath, oxygen saturation drops sharply during exercise. Computed tomography (CT) in such cases usually shows bilateral ground glass opacity, which indicates edema. Some authors attribute this to the loss of pulmonary vasoconstriction, one of the reasons for which may be the effect of histamine on H2 receptors of pericytes and/or on vascular smooth muscle cells. Additional causes may be edema due to the acti vation of H1 receptors, and microthrombosis of the pulmonary vessels. Such patients benefit from prone position, while positive end expiratory pressure (PEEP) ventilation cannot help due to the lack of recruited alveoli [54] . At this stage, the patient is at greatest risk of developing serious complications, primarily ARDS with its 60-80% mortality rate. In addition, patients may develop neurological symptoms and complications, including ischemic stroke [55] [56] [57] . Complica tions of the cardiovascular system in the later stages of COVID 19 disease include myocarditis, acute myocardial infarction, heart failure, arrhythmias, and venous thromboembolic events [58, 59] .

The expression patterns of genes of the lung cells and of some blood cells give an idea of which cells can be infected and which of them are exposed to the action of histamine [60] . Accord ing to these data, epithelial cells (of airways, pneumocytes types 1 and 2) and vascular EC (including lymphatic cells) are more likely to be infected, based on the expression patterns of ACE2 and TMPRSS2 in these cell types. The cells with the highest expression of H1 receptors belong to the arterial endothelium. The expres sion of H1 receptors is significantly less on the endothelium of other vessels: pericytes, type 1 pneumocytes, vascular smooth muscle cells and myeloid granulocytes (including mast cells, neu trophils, and eosinophils), and is completely absent in venous vessels. The cells with the highest expression of H2 receptors are, first of all, type 1 pericytes, followed by smooth muscle cells, myeloid granulocytes and type 2 pericytes, type 2 pneumocytes, and only then vascular endothe lium. Similar to H1 receptors, the expression of H2 receptors is also completely absent in venous vessels. We also should note the H4 receptors in the EC of the vessels (the maximum expression level is in the lymphatic cells), in type 1 pneumo cytes, and in smooth muscle cells [60] . This data should be treated with great caution, since they were obtained on mouse embryos, and the dynamics of expression of these proteins or corre sponding genes under the action of viruses, ROS, histamine and other pathogenetic factors or bio logically active substances has not been studied.

Interaction with histamine and bradykinin receptors causes an increase in endothelial per meability through signaling pathways activating Akt1 kinase [61] . In addition, H2 receptor acti vates inositol metabolism through the Gq/11 pro teins, which causes an increase in the concentration of Ca 2+ in the cytosol and an increase in the permeability of the endothelial monolayer; this effect is reduced in the case of pretreatment of EC with famotidine [62, 63] . His tamine has a decisive effect on the state of EC of microvessels and blood tissue barriers, especially in organs such as the lungs and the brain. The effect on histamine H1 and H2 receptors leads to a decrease in the expression of claudin 1, which is the most important protein of tight junc tions, and, as a consequence, to an increase in the permeability of the endothelial monolayer [64] . In addition to the functional response through action on histamine receptors, the ability of EC to metabolize histamine via monoamine oxidase (hydrogen peroxide is one of the products of this metabolism) is of great importance, along with the ability to capture histidine (capture can be enhanced by adding zinc sulfate) and to synthe size histamine using histidine decarboxylase [64] . In our studies, it was found that NADPH oxidase inhibitors suppress the excessive secretion of vWF by EC, induced by histamine [65]. It was previ ously shown that inhibition of ROS generation by type 2 NADPH oxidase (NOX2) reduces the intensity of inflammatory processes in the lungs when the body is affected by the virus of influenza A [66] . In numerous studies, hypercoagulability was noted in patients with COVID 19 and a new type of pulmonary coagulopathy was even identi fied, which manifests itself as microthrombosis of small vessels.

It was found that more than 50% of patients who died from COVID 19 had pulmonary micro thrombosis [67] . This kind of thrombosis was detected not only in arterial vessels, but also in alveolar capillaries, in the absence of inflamma tion and ARDS [68] . Since small microthrombi are difficult to identify on CT, preliminary diag nosis is also difficult. Laboratory coagulation tests usually show normal or slightly increased pro thrombin time and activated partial thromboplas tin time, normal, increased or slightly decreased platelet count, but markedly increased levels of fibrinogen and especially D dimers [69] . Some authors call this condition a variant of dissemi nated intravascular coagulation (DIC), but in fact, pulmonary microthrombosis in COVID 19 is not associated with bleeding, which is one of the signs of DIC, but rather resembles a hypercoagulable state. This coagulopathy appears to be a major component of the pathogenesis of COVID 19, since elevated D dimer levels, along with elevated IL 6 and CRP levels, correlate with prognosis severity. However, in general, the mechanism of formation of pulmonary microthrombosis in COVID 19 remains unclear.

It is important to note that the level of IgG begins to rise within 4 days of the onset of symp toms of COVID 19, indicating secondary antigen exposure. The rapid rise in specific neutralizing antibodies beginning less than 7 days after expo sure to SARS CoV 2 indicates a secondary mobi lization of an already existing population of memory cells, rather than a primary B cell response. SARS CoV 2 reactive CD4+ T cells were found in about 40-60% of people who had not been exposed to the virus, which suggests cross recognition by memory cells of both com mon "cold" coronaviruses and SARS CoV 2 [70] . If pre existing cross reactive IgE antibodies to cold viruses and/or relevant populations of memory B cells are also present in the blood, this can increase dysfunctional degranulation of mast cells. Antibodies produced by an early and rapid humoral response can also stimulate mast cell degranulation. During this phase, an increase in the level of D dimers correlates with the level of CRP and IL 6, and ultimately with a severe out come of the disease.

The researchers of the Immunology Depart ment of the Institute of Experimental Medicine (St. Petersburg, Russia) have shown that Fc gamma receptors of mast cells ensure their activation and release of histamine not only under the influence of IgG containing immune complexes, but also under the influence of CRP, which binds to these receptors [71] . This finding explains the mecha nism of the development of allergic reactions in inflammatory processes in a non immunocom plex way. Thus, any acute phase reaction is fraught with the activation of mast cells and the occurrence of allergic, and possibly anaphylactic reactions. This conclusion is important both theo retically and practically, because indicates the direction for the development of new methods of pharmacological prevention of allergic complica tions in inflammatory diseases of children and adults. Vaccination is undoubtedly among the risk factors for such complications, since the inflam matory response of the body to the vaccine in the presence of a relatively high titer of IgG antibod ies can provoke a redistribution of mast cells and the release of histamine, which can lead to activa tion of EC, the release of vWF, followed by thrombosis.

The development of drugs for the therapy of COVID 19 is one of the main problems of mod ern pharmacology. The main efforts are directed to the development of etiotropic therapy, because the drugs of this series available to pharmacolo gists (remdesivir and various monoclonal anti bodies) have a significant drawback: they must be administered intravenously. In early 2021, it was shown that the ribonucleoside analogue mol nupiravir blocks the transmission of SARS CoV 2 in ferrets [72] . And already in early October 2021, Ridgeback

Biotherapeutics and Merck announced that their drug molnupiravir reduced hospital admissions among high risk patients with COVID 19 by 50% and significantly reduced mortality [73] . Molnupiravir can be taken orally twice a day for five days. More recently, Astra Zeneca announced that its "cocktail of antibod ies" prevents the severe form of COVID 19 [74] . It is known that the effectiveness of etiotropic therapy largely depends on the timely start.

Given the available information on the involve ment of mast cells and the role of histamine in the pathogenesis of COVID 19, the development of pathogenetic therapy using H2 receptor antago nists appears to be a much more reliable prospect. According to the first reports published in the pop ular scientific press and based on unverified data from China [75] , only famotidine provided a clini cal effect in the treatment of COVID 19, while other H2 receptor antagonists (for example, cimetidine) did not. This fact made it possible to suggest that famotidine acts not only on H2 recep tors. In particular, its binding to sigma receptors was tested, along with the possible inhibition of SARS CoV 2 replication [8] . The mechanism of neutralization of SARS CoV 2 through the direct interaction of famotidine with the active centers of viral proteases, in particular, with the papain like protease PLpro and the 3 chymotrypsin like protease Mpro, was also discussed [76, 77] . According to other researchers, this mechanism of action of famotidine as a component of etiotro pic therapy is not proven, and the search for real mechanisms of its positive effect should be carried out from the standpoint of pathogenetic therapy, taking into account, first of all, the interaction of famotidine with H2 receptors [78] . At the same time, discussion of the efficacy of famotidine as an antagonist of H2 receptors often boils down to a discussion of its antacid properties associated with inhibition of the proton pump [79] [80] [81] .

As a result of a comprehensive study, it was found that famotidine does not bind to the SARS CoV 2 proteases and does not suppress the activ ity of SARS CoV 2 in other way, as a result of direct interaction with it. The action of famoti dine is not mediated by sigma 1/2 receptors nei ther; however, the high selectivity of famotidine for H2 receptors with an affinity of about 14 nM was confirmed, which is a significantly higher affinity of cimetidine for H2 receptors (590 nM). Additionally, it was found that famotidine is an inverse agonist of H2 receptor, and, unlike cimetidine, blocks Gs protein signaling by recruiting arrestin [8, 82] . These features of famotidine fundamentally distinguish it from cimetidine and, possibly, from other H2 receptor blockers; the pronounced activation of arrestin by antagonists of G protein coupled receptors (GPCR) is not unique, however is not wide spread. In addition, famotidine abolished H2 receptor mediated negative effects on cytokine production, especially TNF α and interferon γ, reducing lipopolysaccharide induced TNF α production and B7 1 expression on monocytes, as well as inhibitory effects of histamine on Th1 mediated release cytokines.

Another point of application of famotidine is a decrease in neutrophil reactivity [83] . Innate cel lular immunity is the most important element of antiviral defense. Neutrophils not only serve as a marker of acute infection, but also serve as a source of neutrophil extracellular traps (NET), playing a key role in the development of throm botic complications due to the so called NETotic transformation. In samples of the lungs, kidneys and hearts of patients who died due to COVID 19, microvascular thrombi contained a large number of neutrophils [83, 84] . ROS of neutrophils are considered to be a trigger of NETosis, but antago nists of H2 receptors, including famotidine and cimetidine, reduce neutrophil activation and its consequences [85] . Famotidine dose dependently reduces the level of intracellular cal cium in neutrophils and the intensity of ROS gen eration [86] . This fact explains the clinical observations according to which famotidine reduces the level of D dimers and the likelihood of developing pulmonary embolism in COVID 19 [83, 86] .

Nevertheless, information on the effectiveness of famotidine in the treatment of patients with COVID 19 in a clinical setting is rather contra dictory: along with sufficiently convincing data on its positive effect [87, 88] , there is no less convinc ing information about the lack of effectiveness of this drug [89] [90] [91] [92] . However, it is important to note that the dose of intravenous famotidine used in multicenter clinical trial MATCH (Molecular Analysis for Therapy Choice) was 360 mg/day. This dose is almost 10 times higher than the oral dose of famotidine, usually used in the treatment of peptic ulcer disease [75, 93] , while its positive effects have been noted when taken orally at doses of 20-40 mg/day [87] . Moreover, in MATCH study, the use of famotidine was accompanied by the use of 200 mg hydroxychloroquine in the con trol and experimental groups. Although famoti dine is a proven safe drug, excessive suppression of gastric acid secretion can cause pneumonia [94] .

If the pathogenesis of COVID 19 is associated with dysfunctional degranulation of mast cells, then the use of a variety of pharmaceuticals used to treat diseases associated with mast cells will help reduce the mortality and severity of diseases associated with SARS CoV 2 infection. These include drugs that stabilize the activity of mast cells, such as: antagonists of beta 2 adrenergic receptors [95] and cromolyn sodium (cromoglicic acid) [96, 97] , other histamine antagonists (for example, H1 and H4) [49, 98, 99] , antagonists of leukotriene receptors [100] , anti inflammatory agents used in intestinal diseases and inhibitors of mast cell activation [101, 102] . If such agents are used in combination with pharmaceuticals that directly suppress the replication of SARS CoV 2, then it will be possible to develop effective, safe and effective outpatient methods for the preven tion and pathogenetic therapy of COVID 19.

The use of famotidine in combination with oseltamivir as a means of pathogenetic therapy when mice are infected with the viral strain A/ PR/8/34, which causes a disease in mice similar to COVID 19 in humans, increases survival, improves the dynamics of animal body weight, and helps to reduce the level of NKT cells and an increase in the level of naive T helpers. Further studies of famotidine in vivo should be aimed at optimizing the regimen of drug use at a higher viral load, based on the fact that the effect on ani mal survival will be more noticeable with the cor responding indicators in the comparison groups not exceeding 50%, as well as with a longer use of famotidine. 

These studies were supported by the State assignment AAAA A18 118012290142 9.

The authors declare no obvious and potential conflicts of interest related to the publication of this article. 

COVID 19 Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneu monia

Renin Angiotensin Aldosterone System Inhibitors in Patients with Covid 19

CD209L/ L SIGN and CD209/DC SIGN Act as Receptors for SARS CoV 2

Neuropilin 1 is a host factor for SARS CoV 2 infection

CD147 spike protein is a novel route for SARS CoV 2 infection to host cells

Famoti dine

Sudden and Complete Olfactory Loss of Function as a Possible Symptom of COVID 19

HLH Across Speciality Collaboration UK (2020) COVID 19: consider cytokine storm syndromes and immunosuppres sion

A tug of war between severe acute respira tory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses

Rapid induction of inflamma tory lipid mediators by the inflammasome in vivo

Pro resolving lipid mediators are leads for resolution physiology

Inflammation resolution: a dual pronged approach to averting cytokine storms in COVID 19?

Histamine, histamine receptors, and neu ropathic pain relief

Critical role of endogenous histamine in promoting end organ tissue injury in sepsis

Pathological inflammation in patients with COVID 19: a key role for monocytes and macrophages

Immune mechanisms of pulmonary intravascular coagulopathy in COVID 19 pneumonia

Mast cells contribute to coronavirus induced inflammation: new anti inflammatory strategy

Mast cells activated by SARS CoV 2 release histamine which increases IL 1 levels causing cytokine storm and inflamma tory reaction in COVID 19

Diagnosis of mast cell activation syndrome: a global "consensus 2

Mast cell activation syndrome: tools for diagnosis and differential diagnosis

Mast cell activation syn drome: a primer for the gastroenterologist

Original antigenic sin and apoptosis in the patho genesis of dengue hemorrhagic fever

Dengue: status of current and under development vaccines

Kounis syndrome: an update on epidemiology, pathogenesis, diagnosis and therapeutic management

Mast Cells in Alveo lar Septa of COVID 19 Patients: A Pathogenic Pathway That May Link Interstitial Edema to Immunothrombosis

Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low pathogenicity vaccine strain

Anti influenza effect and action mechanisms of the chemical constituent gallocat echin 7 gallate from Pithecellobium clypearia Benth

A rapid, simple, and humane method for subman dibular bleeding of mice using a lancet

Natural killer T (NKT) B cell interactions promote prolonged antibody responses and long term memory to pneumococcal capsular polysaccharides

Eosinophil mediated lung inflammation associated with elevated natural killer T cell response in COVID 19 patients

Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID 19) in Wuhan, China

Pro and Anti Inflammatory Responses in Severe COVID 19 Induced Acute Respiratory Distress Syndrome An Observational Pilot Study

Physiologi cal and pathological regulation of ACE2, the SARS CoV 2 receptor

Pulmonary pathology of early phase 2019 novel coronavirus (COVID 19) pneumonia in two patients with lung cancer

Pul monary pathology of early phase COVID 19 pneumonia in a patient with a benign lung lesion

Forskolin inhibits the release of histamine from human basophils and mast cells

Histamine inhibits tumor necrosis factor alpha release by mast cells through H2 and H3 receptors

The mystery of the pan demic's 'happy hypoxia

Impli cations for forensic death investigations from first Swiss post mortem CT in a case of non hospital treatment with COVID 19

The early natural history of SARS CoV 2 infection: clinical observations from an urban, ambulatory COVID 19 clinic

COVID 19 pneumonia: ARDS or not?

Neurological complications of coronavirus disease (COVID 19): encephalopathy

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Management of acute ischemic stroke in patients with COVID 19 infection: Report of an international panel

Cardiovascular complications in COVID 19

Management of Acute Myocar dial Infarction During the COVID 19 Pandemic: A Position Statement From the Society for Car diovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP)

Lung GENS': a web based tool for mapping single cell gene expression in the developing lung

Akt1 is critical for acute inflammation and histamine mediated vas cular leakage

International union of basic and clinical pharmacology. XCVIII. Histamine recep tors

Histamine H2 recep tor activation exacerbates myocardial ischemia/ reperfusion injury by disturbing mitochondrial and endothelial function

Elucidation of New Function in Endothelial Cells for Efficient Delivery Strategy of Drug to Tissues

VAS2870 Inhibits Hista mine Induced Calcium Signaling and vWF Secre tion in Human Umbilical Vein Endothelial Cells

Pulmo nary post mortem findings in a large series of COVID 19 cases from Northern Italy

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID 19 infection: A report of five cases

Hypercoagulability of COVID 19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis

Targets of T Cell Responses to SARS CoV 2 Coronavirus in Humans with COVID 19 Disease and Unexposed Individuals

Factors of the acute phase of inflammation as modulators of the interaction of mast cells and fibroblasts

Thera peutically administered ribonucleoside analogue MK 4482/EIDD 2801 blocks SARS CoV 2 transmission in ferrets

What we know-and don't know-about Merck's new Covid 19 pill

Covid 19: AstraZeneca says its anti body drug AZD7442 is effective for preventing and reducing severe illness

New York clinical trial quietly tests heartburn remedy against coronavirus

Class A G Protein Coupled Receptor Antagonist Famotidine as a Therapeutic Alternative Against SARS CoV2: An In Silico Analysis

Analysis of therapeutic tar gets for SARS CoV 2 and discovery of potential drugs by computational methods

What Underlies the Benefit of Famotidine Formula tions Used During COVID 19?

A Birds Eye (Re)View of Acid Suppres sion Drugs, COVID 19, and the Highly Variable Literature

Acid pH Increases SARS CoV 2 Infection and the Risk of Death by COVID 19

Comparative Effectiveness of Famotidine in Hospitalized COVID 19 Patients

Physiological implications of biased signaling at histamine H 2 receptors

Neu trophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID 19 (2020)

Pneumonia Is Associated With Respiratory Fail ure and Coagulopathy

The effects of cimetidine, ranitidine, and famotidine on human neutrophil functions

Hospital ized COVID 19 Patients Treated With Celecoxib and High Dose Famotidine Adjuvant Therapy Show Significant Clinical Responses

SSRN

Famotidine Research Group (2020) Famotidine Use Is Asso ciated With Improved Clinical Outcomes in Hos pitalized COVID 19 Patients: A Propensity Score Matched Retrospective Cohort Study

Impact of Famotidine Use on Clinical Outcomes of Hos pitalized Patients With COVID 19

The association between famotidine and in hospi tal mortality of patients with COVID 19

Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID 19 Patients? A Sys temic Review and Meta Analysis

Asso ciation Between Famotidine Use and COVID 19 Severity in Hong Kong: A Territory wide Study

Comparative Effectiveness of Famotidine in Hospitalized COVID 19 Patients

A Multi site, Randomized, Double Blind, Com parative Trial of the Safety and Efficacy of Stan dard of Care (SOC) Plus Famotidine vs SOC Plus Placebo for the Treatment of COVID 19 in Hospi talized Adults

Use of acid suppressive drugs and risk of pneumonia: a systematic review and meta analysis

Desensitisation of mast cell beta2 adrenoceptor mediated responses by salmeterol and formoterol

Mast cell stabilisers

The thera peutic effects of sodium cromoglycate against influenza A virus H5N1 in mice

In vitro effects of H1 antihis tamines on histamine and PGD2 release from mast cells of human lung, tonsil, and skin

Dual histamine receptor blockade with ceti rizine-famotidine reduces pulmonary symptoms in COVID 19 patients

As a potential treat ment of COVID 19: Montelukast. Med Hypothe ses 142:109828

Mast Cell Activa tion Syndrome and Mastocytosis: Initial Treat ment Options and Long Term Management

Recent advances in our understanding of mast cell activa tion-or should it be mast cell mediator disorders?